Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript
Summarize this article with:
SA Transcripts157.57K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 January 8, 2026 4:30 PM EST Company Participants Stephane Paquette - Vice President of Corporate DevelopmentKrish Krishnan - Founder, Chairman, President & CEOSuma Krishnan - Founder, President of R&D and DirectorDavid SweetTrevor Parry Conference Call Participants Jorge LascanoRitu Baral - TD Cowen, Research DivisionJiale Song - Jefferies LLC, Research DivisionAlec Stranahan - BofA Securities, Research DivisionGautam Chukka - Evercore ISI Institutional Equities, Research DivisionSamantha Corwin - William Blair & Company L.L.C., Research DivisionJoseph Pantginis - H.C. Wainwright & Co, LLC, Research DivisionYigal Nochomovitz - Citigroup Inc., Research DivisionAndrea Tan - Goldman Sachs Group, Inc., Research Division Presentation Operator Thank you for standing by, and welcome to Krystal Biotech's Clinical Update Call for Cystic Fibrosis program, KB407. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development. Stephane PaquetteVice President of Corporate Development Good afternoon, and thank you all for joining today's call. Earlier today, we announced positive interim clinical results for Krystal Biotech's cystic fibrosis program, KB407, including molecular confirmation of wild-type CFTR protein expression in patients' lungs. The press release is available on our website at www.krystalbio.com. Both the press release and today's presentation have also been filed as an 8-K with the SEC. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Trevor Parry, Vice President of Product Development; David Sweet, Director of Clinical Development; and Dr. Jorge Lascano, Professor of Medicine, Associate Director of the Adult Cystic Fibrosis Program and Director of the Cystic Fibrosis Therapeutics Development Center at the University of Florida. This conference call will and our